Table 3 Comparison of SCT and no-SCT... | American Society of Hematology

Table 3

Comparison of SCT and no-SCT patient outcomes in prespecified patient subsets (time-dependent analysis)

	Patients	SCT patients	CIR HR*	95% CI	P*	RFS HR*	95% CI	P*	OS HR†	95% CI	P†
All patients	522	282	0.50	0.35-0.70	<.001	0.80	0.60-1.06	.12	0.76	0.57-1.02	.069
B-ALL	343	183	0.54	0.35-0.84	.006	0.81	0.57-1.15	.23	0.75	0.53-1.0	.11
T-ALL	179	99	0.42	0.23-0.76	.004	0.76	0.46-1.26	.29	0.79	0.46-1.35	.39
Age 15-44 y	414	226	0.45	0.31-0.66	<.001	0.77	0.55-1.06	.11	0.74	0.53-1.04	.085
Age 45-55 y	108	56	0.74	0.32-1.68	.46	0.93	0.52-1.66	.81	0.84	0.46-1.52	.56
CNS disease at diagnosis	55	32	0.40	0.14-1.18	.096	1.20	0.50-2.90	.68	1.13	0.50-2.57	.77
Complex karyotype	51	25	0.80	0.25-2.55	.70	1.60	0.65-3.92	.30	1.36	0.55-3.40	.50
WBC ≥3 × 10⁹/L (B-ALL)	131	73	0.65	0.35-1.21	.18	0.74	0.43-1.28	.28	0.60	0.35-1.01	.056
CD10^– immature ALL (B-ALL)	125	77	1.14	0.50-2.60	.75	1.64	0.86-3.12	.14	1.09	0.59-2.02	.78
t(4;11)/MLL gene rearrangement (B-ALL)	69	46	0.50	0.20-1.26	.14	0.71	0.33-1.56	.40	0.48	0.24-0.98	.044
t(1;19) (B-ALL)	23	12	0.26	0.05-1.30	.10	0.37	0.09-1.49	.16	0.41	0.10-1.72	.22
Resistance to steroid prephase	199	115	0.63	0.37-1.05	.077	0.85	0.55-1.32	.48	0.81	0.51-1.30	.39
Poor early BM blast clearance	307	175	0.57	0.37-0.86	.008	0.67	0.47-0.97	.034	0.65	0.44-0.95	.028
Late CR	19	13	0.46	0.20-1.02	.055	0.40	0.19-0.83	.014	0.21	0.05-0.80	.023

	Patients	SCT patients	CIR HR*	95% CI	P*	RFS HR*	95% CI	P*	OS HR†	95% CI	P†
All patients	522	282	0.50	0.35-0.70	<.001	0.80	0.60-1.06	.12	0.76	0.57-1.02	.069
B-ALL	343	183	0.54	0.35-0.84	.006	0.81	0.57-1.15	.23	0.75	0.53-1.0	.11
T-ALL	179	99	0.42	0.23-0.76	.004	0.76	0.46-1.26	.29	0.79	0.46-1.35	.39
Age 15-44 y	414	226	0.45	0.31-0.66	<.001	0.77	0.55-1.06	.11	0.74	0.53-1.04	.085
Age 45-55 y	108	56	0.74	0.32-1.68	.46	0.93	0.52-1.66	.81	0.84	0.46-1.52	.56
CNS disease at diagnosis	55	32	0.40	0.14-1.18	.096	1.20	0.50-2.90	.68	1.13	0.50-2.57	.77
Complex karyotype	51	25	0.80	0.25-2.55	.70	1.60	0.65-3.92	.30	1.36	0.55-3.40	.50
WBC ≥3 × 10⁹/L (B-ALL)	131	73	0.65	0.35-1.21	.18	0.74	0.43-1.28	.28	0.60	0.35-1.01	.056
CD10^– immature ALL (B-ALL)	125	77	1.14	0.50-2.60	.75	1.64	0.86-3.12	.14	1.09	0.59-2.02	.78
t(4;11)/MLL gene rearrangement (B-ALL)	69	46	0.50	0.20-1.26	.14	0.71	0.33-1.56	.40	0.48	0.24-0.98	.044
t(1;19) (B-ALL)	23	12	0.26	0.05-1.30	.10	0.37	0.09-1.49	.16	0.41	0.10-1.72	.22
Resistance to steroid prephase	199	115	0.63	0.37-1.05	.077	0.85	0.55-1.32	.48	0.81	0.51-1.30	.39
Poor early BM blast clearance	307	175	0.57	0.37-0.86	.008	0.67	0.47-0.97	.034	0.65	0.44-0.95	.028
Late CR	19	13	0.46	0.20-1.02	.055	0.40	0.19-0.83	.014	0.21	0.05-0.80	.023

HR in SCT vs no-SCT cohort by the Andersen-Gill model.

†

OS comparisons were performed using a 45-day landmark period, excluding patients who died or relapsed during the first 45 days following CR achievement from comparisons (see “Statistical methods” section).

View Large

This Feature Is Available To Subscribers Only